DaVita (NYSE:DVA) Releases Earnings Results, Beats Estimates By $0.14 EPS

DaVita (NYSE:DVA) posted its quarterly earnings results on Tuesday. The company reported $4.02 EPS for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14, FiscalAI reports. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.50 billion. During the same quarter in the previous year, the firm posted $2.95 EPS. DaVita’s revenue was up 5.2% on a year-over-year basis. DaVita updated its FY 2026 guidance to 14.100-15.200 EPS.

Here are the key takeaways from DaVita’s conference call:

• DaVita reaffirmed its 2026 guidance, including adjusted operating income of $2.2 billion at the midpoint and adjusted EPS of $14.65. Management expects fourth-quarter adjusted operating income to exceed third-quarter results by $50 million to $100 million, primarily due to IKC timing.
• Treatment-volume growth accelerated, supported by sustained improvements in patient mortality. DaVita now expects 2026 treatment growth near the top of its prior 25–50 basis-point range, or roughly 50–75 basis points after normalizing for calendar effects.
• DaVita plans to broadly deploy expanded hemodialysis using Nipro’s newly approved medium cut-off dialyzer in the coming quarters. The technology is compatible with existing machines, supply has been secured, and management believes any meaningful financial upside from lower mortality would begin around 2028.
• Revenue per treatment declined sequentially because of lower commercial insurance mix following the expiration of ACA subsidies and reduced phosphate-binder revenue. Management continues to estimate a roughly $40 million 2026 headwind from commercial-mix changes, potentially increasing to $70 million in 2027.
• The transition of phosphate binders into the Medicare bundle has reduced reliance on less-effective over-the-counter treatments by more than 50%, while lowering DaVita’s related revenue and costs. Management supports the policy and expects the final 2027 ESRD payment rule to determine the ultimate financial impact.

DaVita Trading Down 18.4%

Shares of DaVita stock traded down $42.00 on Wednesday, hitting $185.99. 2,131,826 shares of the company traded hands, compared to its average volume of 949,095. DaVita has a 12-month low of $101.00 and a 12-month high of $247.49. The firm’s 50-day simple moving average is $219.11 and its 200 day simple moving average is $175.36. The company has a market cap of $11.94 billion, a P/E ratio of 17.34, a P/E/G ratio of 0.77 and a beta of 0.88.

Analyst Ratings Changes

A number of equities analysts have weighed in on DVA shares. TD Cowen increased their target price on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research report on Monday, May 11th. Truist Financial increased their target price on DaVita from $205.00 to $250.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Barclays boosted their price objective on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research note on Wednesday. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a report on Monday, June 8th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $265.00 price target on shares of DaVita in a research report on Wednesday. Two investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $225.00.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the sale, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at $25,440,571.40. This trade represents a 27.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On DaVita

A number of large investors have recently added to or reduced their stakes in DVA. Invesco Ltd. raised its position in DaVita by 2.0% during the 3rd quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock valued at $223,122,000 after purchasing an additional 32,358 shares during the last quarter. Morgan Stanley grew its holdings in shares of DaVita by 5.1% during the 4th quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock worth $167,807,000 after acquiring an additional 71,156 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of DaVita by 0.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,089,100 shares of the company’s stock valued at $123,733,000 after purchasing an additional 3,507 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in DaVita by 109.7% during the third quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock valued at $73,585,000 after buying an additional 289,725 shares during the period. Finally, Corient Private Wealth LLC lifted its position in DaVita by 1,493.1% during the 4th quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock valued at $40,706,000 after acquiring an additional 335,809 shares during the period. Institutional investors own 90.12% of the company’s stock.

Trending Headlines about DaVita

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: DaVita reported second-quarter adjusted EPS of $4.02, above the roughly $3.88–$4.01 analyst consensus, while revenue reached $3.554 billion, ahead of expectations and up 5.2% year over year. Adjusted operating income was $579 million and free cash flow was $256 million. DaVita Inc. 2nd Quarter 2026 Results
• Positive Sentiment: Management highlighted clinical-led treatment-volume growth, improved patient outcomes and broader access to “middle molecule” therapies as factors supporting future performance. The company also maintained its strategic focus on dialysis innovation. DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth
• Positive Sentiment: Barclays raised its price target from $218 to $224, although it retained an “equal weight” rating. Unusually high call-option activity also indicates increased speculative interest in DVA. Barclays Price Target Update
• Neutral Sentiment: DaVita reaffirmed 2026 adjusted EPS guidance of $14.10–$15.20, adjusted operating income of $2.15–$2.25 billion and free cash flow of $1.0–$1.25 billion. The midpoint remains close to analyst expectations, but management did not raise the outlook after a strong quarter.
• Negative Sentiment: U.S. dialysis revenue per treatment declined sequentially to $415.87 from $417.59, reflecting payer-mix changes and normal fluctuations. Investors also noted higher general and administrative expenses and ongoing reimbursement pressure.
• Negative Sentiment: The market reaction suggests expectations had been elevated ahead of earnings: the earnings and revenue beats were not enough to offset disappointment over the lack of a guidance increase. DaVita Slides as Solid Q2 Results Fail to Lift Full-Year Outlook

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.